Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00823602|
Recruitment Status : Unknown
Verified January 2009 by Yazd Research & Clinical Center for Infertility.
Recruitment status was: Recruiting
First Posted : January 15, 2009
Last Update Posted : January 15, 2009
Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients. Up to now, however not enough prospectives have been published to prove any beneficial effect of antagonists on the first cycle assisted reproductive technique.
This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.
The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: ganirelix Drug: suprefact||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART|
|Study Start Date :||March 2008|
|Actual Primary Completion Date :||October 2008|
|Estimated Study Completion Date :||January 2009|
GnRH antagonist "ganirelix" 0.25 mg fromm 6th ovarian stimulation
These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
Active Comparator: 2
GnRH agonist, suprefact, stimulation with a standard long protocol
GnRH agonist, standard protocol
- pregnancy rate [ Time Frame: 2weeks ]
- ovarian stimulation [ Time Frame: 10days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00823602
|Contact: razieh firouzabadi, MD||8247085 ext +email@example.com|
|Contact: shahnaz Ahmadi, MD||9173717981 ext +98||AHMADISHAHNAZ2005@yahoo.com|
|Iran, Islamic Republic of|
|Yazd Research and Clinical Center For Infertility||Recruiting|
|Yazd, Iran, Islamic Republic of|
|Contact: razieh firouzabadi, MD 8247085 ext +98351 firstname.lastname@example.org|
|Contact: shahnaz Ahmadi, MD 9173717981 ext +98 AHMADISHAHNAZ2005@yahoo.com|
|Principal Investigator: shahnaz ahmadi, MD|
|Study Chair:||razieh firouzabadi, MD||Yazd Research & Clinical Center for Infertility|